Isomorphic Labs Raises $5 Billion to Move AI-Designed Drug Candidates Toward the Clinic

Isomorphic Labs has raised $5 billion in a Series C funding round, the company announced on 17 November 2026. The round was co-led by Greenoaks and Sequoia Capital, according to TechCrunch, which also reported that Andreessen Horowitz joined as a new investor. The company did not disclose its new valuation.
Existing backers GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also invested in the round. The Series C follows a $2.1 billion Series B round that the company announced on 12 May 2026.
Isomorphic Labs was spun out of Google's DeepMind in 2021. Demis Hassabis is its founder and CEO. He left his position as head of DeepMind to focus on drug discovery and moved into a chairman role at DeepMind.
The company said it will use the new capital to keep developing its drug-design engine, the software that proposes and scores candidate molecules, and to expand into more types of medicine. Its stated near-term goal is to move drug candidates into clinical trials, which are studies in human volunteers and patients. It said its program has produced positive preclinical results in oncology and immunology. Preclinical work happens before human testing, in the lab and in model systems. Those results have not yet been tested in patients, and the company has not said when its first trials will begin.
Isomorphic Labs has also built a partnership roster that includes Eli Lilly, Novartis and Johnson & Johnson. Its news page dates the Johnson & Johnson research collaboration to 20 January 2026. In October 2026, the company announced it had joined the Virtual Biology Initiative, an effort to build foundational data for AI models that predict and treat disease. That announcement is dated 7 October 2026.
The broader context here is the gap between a computational result and a clinical one. A model's predictions can hold up in the lab, but that evidence carries a different weight from human trial data, where toxicity, dosing and efficacy must be shown in patients. For an AI-driven discovery company, the move into the clinic is the point at which its design engine is judged by outcomes rather than by benchmarks and assay readouts.
The scale of the raise is also a signal about where capital in AI-for-science is flowing. A round of this size, with growth-stage venture firms, a sovereign-linked fund and a public-sector AI vehicle in the cap table, suggests that investors see drug discovery as a durable destination for large model-driven platforms. The undisclosed valuation leaves open how the market is pricing that expectation.
In my view, the number that matters most over the next several years will be how many candidates reach the clinic and how many of those produce usable medicines, rather than the size of the round. Funding at this scale gives the company room to run more programs in parallel and to widen the range of disease areas it addresses. Whether that breadth translates into treatments depends on trials that will take years to read out.
For practitioners, the story is less about the headline figure than about the handoff it anticipates. A drug-design engine with positive preclinical signals in oncology and immunology now has to survive translation into human biology, with partners such as Eli Lilly, Novartis and Johnson & Johnson positioned to shape which programs advance. If the company succeeds, the payoff would be shorter paths from target to candidate for diseases that have resisted conventional screening. That is the outcome the new capital is meant to make possible, and it is the outcome the coming trials will test.


